For more than a decade, ivWatch has been working on a problem most hospitals don’t fully see, and even fewer can measure.
IV therapy is one of the most common procedures in healthcare. It happens millions of times a day, quietly and routinely. But beneath that routine is a persistent issue. Infiltration and extravasation injuries develop silently, are often misdiagnosed, and frequently go unreported until they become serious. For years, this lived in a gray area of healthcare, clinically real, but operationally invisible.
ivWatch was built to change that.
The Newport News based company developed a continuous monitoring system designed to detect IV complications early, before they escalate into severe injuries. It was a fundamentally different approach to a longstanding problem. Instead of relying on periodic checks, what clinicians call touch, look, compare, ivWatch introduced a constant layer of visibility. Not just checking for problems, but catching them as they begin.
But building the technology was only the first step.
In the early days, the challenge wasn’t just adoption, it was belief. Many clinicians had spent decades in the field without formally recognizing these injuries at scale. Some didn’t see it as a widespread issue. Others had simply never connected the dots between what they were seeing in isolation and the broader pattern across a hospital system. When a problem is underreported and inconsistently measured, it becomes easy to dismiss.
So ivWatch did what most healthcare technologies must do. They proved it clinically.
Over time, as the technology was deployed in real world hospital settings, the data became harder to ignore. A large retrospective study analyzing its use in detecting IV related injuries showed a 93% reduction in injury severity when continuous monitoring was used alongside standard care . Injuries that might have progressed into severe outcomes requiring surgical intervention, extended hospital stays, or worse were being caught earlier and managed before they escalated.
It worked.
But even that wasn’t enough.
Because in healthcare, better outcomes do not automatically drive decisions. Budgets do. Risk does. Reimbursement does. And for all the clinical success ivWatch could point to, there was still a critical question hospitals needed answered. What is this actually worth?
That gap between clinical validation and financial justification has stopped countless innovations from scaling.
Until now.
In March 2026, ivWatch announced a partnership with Aon, one of the world’s leading risk and insurance consulting firms, to quantify the true cost of IV related injuries and model the return on investment for preventing them. By combining ivWatch’s clinical performance data with Aon’s proprietary database of healthcare liability claims and cost benchmarks, the company was able to do something it had never done before. Translate patient outcomes into financial impact.
The results were significant.
The model showed that preventing severe IV injuries could generate annual margin improvements ranging from $5.1 million to $7.9 million for non pediatric hospitals, and as much as $8.9 million to $13.4 million for a 150 bed pediatric hospital . Even under conservative assumptions, the return on investment ranged from 7x to 14x .
For the first time, a problem that had long been difficult to measure was now tied directly to the bottom line.
And that changes everything.
What ivWatch has done is not just validate its technology, it has reframed the conversation. IV injuries are no longer just a clinical concern managed at the bedside. They are a measurable financial risk, with real implications for hospital operations, legal exposure, and patient satisfaction. By making those costs visible, ivWatch has moved from being a clinical tool to a business decision.
That shift opens new doors.
Historically, adoption conversations for technologies like ivWatch lived primarily with clinicians. Now, they extend into risk management teams, finance departments, and executive leadership. The question is no longer just does this improve care, but what does it cost us if we do not implement it.
And in many cases, that answer is measured in millions.
For a region like Hampton Roads, it is another example of a company quietly building something with global implications. What started as a hardware solution developed to solve a specific clinical problem has evolved into a data driven platform influencing how hospitals think about risk, cost, and care delivery.
It is one thing to build technology that improves patient outcomes.
It is another to prove what that improvement is worth.
ivWatch has now done both.
